MedTrace Logo

THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring

NCT01970969 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 928

Last updated 2018-04-17

No results posted yet for this study

Summary

Our primary hypothesis is that a risk score comprised of approximately 10 single nucleotide polymorphisms (SNPs) that are associated with atrial fibrillation at the Genome Wide Association Study (GWAS) level is associated with the development of atrial fibrillation among previously undiagnosed patients at high risk for atrial fibrillation. A current example of these SNPs is shown in Table 1. As a secondary hypothesis, we will test the association between atrial fibrillation diagnosed in this study with a subset of SNPs reported to be associated with atrial fibrillation and with fine-mapping SNPs. We will also test the association between atrial fibrillation of less than and greater than 30 seconds and a panel of approximately 10 SNPs.

Conditions

  • Patients With Symptoms of Cardiac Arrhythmia at Risk for Atrial Fibrillation

Sponsors & Collaborators

  • Quest Diagnostics-Nichols Insitute

    collaborator INDUSTRY

  • Scripps Translational Science Institute

    lead OTHER

Principal Investigators

  • Eric Topol, MD · Scripps Translational Science Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01970969 on ClinicalTrials.gov